Cahill Represents Lead Arrangers in $1.6 Billion Incremental Credit Facility for Horizon Therapeutics USA, Inc.
Date: 03/15/21
Cahill represented the lead arrangers in connection with a $1.6 billion incremental term B credit facility for Horizon Therapeutics USA, Inc., a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Proceeds from the credit facility were used for the acquisition of Viela Bio, Inc., a clinical-stage biotechnology company, and for general corporate purposes.